Analyst Conference Summaries

Biotechnology Investor Aids

Medivation, Inc.
MDVN

conference date: August 9, 2016 @ 1:30 PM Pacific Time

Medivation to be bought to Pfizer at $81.50 [August 22, 2016]

Medivation Rejects Sanofi Offer [April 29, 2016]
Medivation Looks Strong for 2015-2016 [04/09/2015 at Seeking Alpha]

2016
 
 
05/05/2016
08/09/2016
 
 
2015
05/07/2015
08/06/2015
11/05/2015
02/25/2016

Medivation is a manufacturer of a prostate cancer therapy.

Medivation web site


 

Search

More Analyst Conference Pages:

 AGEN
 AGIO
 ALNY
 ALXN
 AMAT
 AMD
 AMGN
 BIIB
 BIND
 CLDX
 CELG
 EPZM
 GILD
 GLYC
 HNSN
 INO
 INTC
 ISRG
 JUNO
 MACK
 MCHP
 MDVN
 MYL.
 NVDA
 OPXA
 PLX
 REGN
 SGEN
 XLNX
 XLRN

 

Disclaimer: Our analyst summaries may include both our condensations of statements made by company representatives and our own analysis. They are not covered by any warranty. We cannot guarantee anything said by company representatives is true. We try not to make errors, but it is possible. This is investment journalism, not financial advice.

Copyright 2015 William P. Meyers